Article
Oncology
Lily Chen, Bhavani S. Gannavarapu, Neil B. Desai, Michael R. Folkert, Michael Dohopolski, Ang Gao, Chul Ahn, Jeffrey Cadeddu, Aditya Bagrodia, Solomon Woldu, Ganesh V. Raj, Claus Roehrborn, Yair Lotan, Robert D. Timmerman, Aurelie Garant, Raquibul Hannan
Summary: This study analyzed the use of stereotactic ablative radiation (SAbR) at a dose of 45 Gy in 5 fractions for prostate cancer. The results showed promising safety profiles, but further prospective studies are needed to establish this dose regimen as standard of care.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Megan E. Daly
Summary: Stereotactic ablative radiotherapy (SABR) is the standard treatment for medically inoperable, early-stage non-small-cell lung cancer. However, regional and distant failures remain a challenge, especially in larger and more biologically aggressive tumors. Use of cytotoxic chemotherapy is limited in this patient population, prompting the investigation of alternative systemic therapy options with fewer side effects, such as immune checkpoint inhibitors.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Mihailo Miljanic, Chika Nwachukwu, Assal Rahimi
Summary: This case series and literature review investigate the efficacy and safety of definitive ablative radiation therapy for non-operable patients with early stage breast cancer. The two cases presented demonstrate the potential of this approach to achieve durable responses.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Mihailo Miljanic, Chika Nwachukwu, Assal Rahimi
Summary: This case series and literature review suggest that definitive ablative radiation therapy may serve as a safe and effective treatment option for non-operable patients with early stage breast cancer. The observed durable treatment responses and minimal toxicity support the potential of this approach.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Medicine, General & Internal
Annaig Bertho, Morgane Dos Santos, Sarah Braga-Cohen, Valerie Buard, Vincent Paget, Olivier Guipaud, Georges Tarlet, Fabien Milliat, Agnes Francois
Summary: By utilizing three-fraction schedules delivered over a period of 1 week with doses per fraction of 20, 28, 40, and 50 Gy, only 3 x 40 Gy or 3 x 50 Gy generated focal lung fibrosis after 6 months. The study suggests that a fractionation schedule using an arc-therapy-delivered three fractions/1 week regimen with 3 x 3 mm beam requires 40 Gy per fraction for lung fibrosis to develop within 6 months.
FRONTIERS IN MEDICINE
(2021)
Article
Oncology
Therese MJ. Kang, Nicholas Hardcastle, Anurag K. Singh, Ben J. Slotman, Gregory M. M. Videtic, Kevin L. Stephans, Felipe Coun Counago, Alexander V. Louie, Matthias Guckenberger, Susan V. Harden, Nikki M. Plumridge, Shankar Siva
Summary: SABR is an effective treatment for inoperable early-stage NSCLC and pulmonary oligometastases. Single-fraction SABR, with its excellent local control and safety profiles, has advantages in terms of resource efficiency and reduced hospital visits, especially during the COVID-19 pandemic.
Article
Oncology
Michael F. Gensheimer, Harriet Gee, Hiroki Shirato, Hiroshi Taguchi, John M. Snyder, Alexander L. Chin, Lucas K. Vitzthum, Peter G. Maxim, Heather A. Wakelee, Joel Neal, Millie Das, Daniel T. Chang, Elizabeth Kidd, Steven L. Hancock, David B. Shultz, Kathleen C. Horst, Quynh-Thu Le, Samantha Wong, Eleanor Brown, Ngan Nguyen, Rachel Liang, Billy W. Loo, Maximilian Diehn
Summary: Stereotactic ablative radiotherapy (SABR) can be individualized based on tumor size, location, and histological characteristics to achieve excellent local control for lung tumors. This nonrandomized controlled trial suggests that individualized SABR may allow minimization of treatment dose and reduce toxic effects.
Article
Multidisciplinary Sciences
Arta M. Monjazeb, Megan E. Daly, Guillaume Luxardi, Emanual Maverakis, Alexander A. Merleev, Alina I. Marusina, Alexander Borowsky, Amin Mirhadi, Stephen L. Shiao, Laurel Beckett, Shuai Chen, David Eastham, Tianhong Li, Logan V. Vick, Heather M. Mcgee, Frances Lara, Leslie Garcia, Leigh Anne Morris, Robert J. Canter, Jonathan W. Riess, Kurt A. Schalper, William J. Murphy, Karen Kelly
Summary: Stereotactic ablative radiotherapy (SABR) is a standard-of-care for medically-inoperable-early-stage non-small cell lung cancer (NSCLC). A phase I study tested the addition of atezolizumab to SABR in high risk, medically inoperable, early-stage NSCLC, and found that it was well tolerated and showed efficacy signals.
NATURE COMMUNICATIONS
(2023)
Article
Oncology
Raquibul Hannan, Michael Christensen, Hans Hammers, Alana Christie, Brendan Paulman, Dandan Lin, Aurelie Garant, Waddah Arafat, Kevin Courtney, Isaac Bowman, Suzanne Cole, David Sher, Chul Ahn, Hak Choy, Robert Timmerman, James Brugarolas
Summary: SAbR treatment can extend the duration of ongoing systemic therapy for mRCC patients with limited progression without compromising quality of life.
EUROPEAN UROLOGY ONCOLOGY
(2022)
Article
Oncology
Raquibul Hannan, Michael Christensen, Alana Christie, Aurelie Garant, Ivan Pedrosa, Liliana Robles, Samantha Mannala, Chiachien Wang, Hans Hammers, Waddah Arafat, Kevin Courtney, Isaac A. Bowman, David Sher, Chul Ahn, Suzanne Cole, Hak Choy, Robert Timmerman, James Brugarolas
Summary: This study evaluated the feasibility of SAbR for patients with systemic therapy-naive oligometastatic RCC and found that SAbR can provide long-term disease control while preserving quality of life for patients.
EUROPEAN UROLOGY ONCOLOGY
(2022)
Review
Oncology
Davide Franceschini, Maria Ausilia Teriaca, Luca Dominici, Ciro Franzese, Marta Scorsetti
Summary: Oligometastatic patients are a heterogeneous group with only some benefiting from local ablative approaches like SABR. Identifying predictive and prognostic features is crucial for guiding clinical practice.
CANCER MANAGEMENT AND RESEARCH
(2021)
Article
Oncology
Shankar Siva, Mathias Bressel, Tao Mai, Hien Le, Shalini Vinod, Harini de Silva, Sean Macdonald, Marketa Skala, Nicholas Hardcastle, Angela Rezo, David Pryor, Suki Gill, Braden Higgs, Kassandra Wagenfuehr, Rebecca Montgomery, Raef Awad, Brent Chesson, Thomas Eade, Wenchang Wong, Giuseppe Sasso, Richard De Abreu Lourenco, Tomas Kron, David Ball, Paul Neeson
Summary: This study aimed to compare the treatment efficacy of single-fraction and multifraction SABR for pulmonary oligometastases, and the results showed no significant differences in safety, efficacy, or symptom burden between the two approaches, with single-fraction SABR being more efficient for delivery.
Article
Oncology
Muhtada Kamal Aldin, Lihong Qi, Xiner Zhou, Leonel A. Kahn, Megan E. Daly
Summary: The development and detection of second primary lung cancer (SPLC) following stereotactic ablative radiotherapy (SABR) may differ from surgical patients. In this study, 134 patients treated with SABR were analyzed, and it was found that the incidence of SPLC was higher than in other published studies. The outcomes of surveillance-detected SPLC were similar to those of de novo early stage lung cancers.
CLINICAL LUNG CANCER
(2022)
Article
Oncology
Henan Zhang, Jacob J. Orme, Feven Abraha, B. J. Stish, Val J. Lowe, Fabrice Lucien, Erik J. Tryggestad, Michael S. Bold, Lance C. Pagliaro, C. Richard Choo, Debra H. Brinkmann, Matthew J. Iott, Brian J. Davis, J. Fernando Quevedo, William S. Harmsen, Brian A. Costello, Geoffrey B. Johnson, Mark A. Nathan, Kenneth R. Olivier, Thomas M. Pisansky, Eugene D. Kwon, Haidong Dong, Sean S. Park
Summary: The study showed that high levels of tumor-reactive T cells and effector memory T cells were associated with better outcomes in oligometastatic CRPC patients treated with SABR. This supports the incorporation of immune-based markers in the design of future randomized trials in this patient population.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Tae Hoon Lee, Dong-Yun Kim, Hong-Gyun Wu, Joo Ho Lee, Hak Jae Kim
Summary: This study compared the efficacy and safety of re-irradiation (re-RT) using stereotactic ablative radiotherapy (SABR) with initial SABR for primary, recurrent lung cancer or metastatic lung tumor. The local control rate was lower in the re-RT group compared to initial SABR, but there was no compromise in survival rates. The toxicity of re-RT using SABR was found to be acceptable.
RADIATION ONCOLOGY
(2021)